| Sitemap | Subscribe | Contact Us | ||
|
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Latest Other Lab Tests Articles
The CLiRpath laser
Peripheral arterial disease (PAD) affects up to 12 million Americans, causing symptoms that range from leg pain to gangrene or ulcerations resulting from lack of blood flow. Untreated, PAD can lead to possible amputation.
A new laser technology may provide an alternative to amputation. Unlike bypass surgery or angioplasty and stenting techniques, the CLiRpath laser can vaporize blockages in the arteries in the leg and foot. According to a press release by CLiRpath maker Spectranetics Corp., in clinical trials, limb salvage was observed in 95 percent of patients surviving to six months in people doing CLiRpath therapy.
For more information, visit the Web site at www.clirpath.com.
2 comments - 16 Apr 2008
Comments...
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register..
Register your Diabetes Health Username here.
Have Your Say...